Antipsychotic drug-induced movement disorders

Canadian Journal of Neurological Sciences

Volumn 30, Issue SUPPL. 1, 2003, Pages

  Blanchet, Pierre J ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; ANTIPARKINSON AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; CISAPRIDE; CYCLOSPORIN; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; FLUOXETINE; FLUPHENAZINE; HALOPERIDOL; LEVODOPA; LITHIUM; METHYLPHENIDATE; METOCLOPRAMIDE; NEUROLEPTIC AGENT; PROCHLORPERAZINE; PROMETHAZINE; RESERPINE; TETRABENAZINE; THYROXINE; UNINDEXED DRUG; VALPROIC ACID; VINCRISTINE;

AKATHISIA; CHOREA; DRUG INDUCED DISEASE; DYSKINESIA; DYSTONIA; HUMAN; INVOLUNTARY MOVEMENT; MOTOR DYSFUNCTION; MUSCLE SPASM; MYOCLONUS; OCULOGYRIC CRISIS; PARKINSONISM; PRIORITY JOURNAL; REVIEW; TARDIVE DYSKINESIA; TIC; TREMOR;

EID: 0037349634     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/s0317167100003309     Document Type: Review

References (52)

1. Owens DGC. A Guide to the Extrapyramidal Side-Effects of Antipsychotic Drugs. Cambridge: Cambridge University Press, 1999.
2. Ayd FJ. A survey of drug-induced extrapyramidal reactions. JAMA 1961;175:1054-1060.
3. Singh H, Levinson DF, Simpson GM, Lo EES, Friedman E. Acute dystonia during fixed-dose neuroleptic treatment. J Clin Psychopharmacol 1990;10:389-396.
4. Chakos MH, Mayerhoff DI, Loebel AD, Alvir J, Lieberman JA. Incidence and correlates of acute extrapyramidal symptoms in first episode of schizophrenia. Psychopharmacol Bull 1992;28: 81-86.
5. Raja M. Managing antipsychotic-induced acute and tardive dystonia. Drug Saf 1998;19:57-72.
6. Tune L, Coyle JT. Acute extrapyramidal side-effects: serum levels of neuroleptics and anticholinergics. Psychopharmacology 1981;75:9-15.
7. Eldridge M. The torsion dystonias: literature review and genetic and clinical studies. Neurology 1970;20:1-78.
8. Swett C. Drug-induced dystonia. Am J Psychiatry 1975;132:532-534.
9. Sethy VH, van Woert MH. Modification of striatal acetylcholine concentration by dopamine receptor agonists and antagonists. Res Commun Chem Pathol Pharmacol 1974;8:13-28.
10. Neale R, Gerhardt S, Liebman JM. Effects of dopamine agonists, catecholamine depletors, and cholinergic and GABAergic drugs on acute dyskinesias in squirrel monkeys. Psychopharmacology 1984;82:20-26.
11. Sachdev P, Kruk J. Clinical characteristics and predisposing factors in acute drug-induced akathisia. Arch Gen Psychiatry 1994;51:963-974.
12. Stephen PJ, Williamson J. Drug-induced parkinsonism in the elderly. Lancet 1984;2:1082-1083.
13. Sethi KD, Zamrini EY. Asymmetry in clinical features of drug-induced parkinsonism. J Neuropsychiatry 1990;2:64-66.
14. Yassa R, Samarthji L. Prevalence of the rabbit syndrome. Am J Psychiatry 1986;143:656-657.
15. Burn DJ, Brooks DJ. Nigral dysfunction in drug-induced parkinsonism: an 18F-dopa study. Neurology 1993;43:552-556.
16. Kornhuber J, Bormann J, Hübers M, Rusche K, Riederer P. Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol - Mol Pharmacol Sect 1991;206:297-300.
17. Silver H, Geraisy N, Schwartz M. No difference in the effect of biperiden and amantadine on parkinsonism- and tardive dyskinesia-type involuntary movements. J Clin Psychiatry 1995;56:167-170.
18. Chiarello RJ, Cole JO. The use of psychostimulants in general psychiatry. Arch Gen Psychiatry 1987;44:286-295.
19. Lieberman JA, Kane JM, Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology 1987;91:415-433.
20. Fenton WS, Blyler CR, Wyatt RJ, McGlashan TH. Prevalence of spontaneous dyskinesia in schizophrenic and non-schizophrenic psychiatric patients. Br J Psychiatry 1997;171:265-268.
21. Owens DGC, Johnstone EC, Frith CD. Spontaneous involuntary disorders of movement. Their prevalence, severity, and distribution in chronic schizophrenics with and without treatment with neuroleptics. Arch Gen Psychiatry 1982;39:452-461.
22. Degkwitz R, Wenzel W. Persistent extrapyramidal side effects after long-term application of neuroleptics. In: Brill H, Cole JO, Deniker P, Hippius H, Bradley PB, (Eds). Neuro-psychopharmacology (International Congress Series no. 129). Amsterdam: Excerpta Medica Foundation, 1967:608-615.
23. Kane JM, Weinhold P, Kinon B, Wegner J, Leader M. Prevalence of abnormal involuntary movements ("spontaneous dyskinesias") in the normal elderly. Psychopharmacology 1982;77:105-108.
24. Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharmacol 1988;8(Aug Suppl):52S-56S.
25. Ganzini L, Heintz RT, Hoffman WF, Casey DE. The prevalence of tardive dyskinesia in neuroleptic-treated diabetics - a controlled study. Arch Gen Psychiatry 1991;48:259-263.
26. Kapitany T, Meszaros K, Lenzinger E, et al. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. Schizophr Res 1998;32:101-106.
27. Lerer B, Segman RH, Fangerau H, et al. Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 2002;27:105-119.
28. Fernandez HH, Krupp B, Friedman JH. The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14-year follow-up. Neurology 2001;56:805-807.
29. Friedman JH, Kucharski LT, Wagner RL. Tardive dystonia in a psychiatric hospital. J Neurol Neurosurg Psychiatry 1987;50:801-803.
30. van Harten PN, Matroos GE, Hoek HW, Kahn RS. The prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia: the Curacao Extrapyramidal Syndromes Study I. Schizophr Res 1996;19:195-203.
31. Kiriakis V, Bhatia KP, Quinn NP, Marsden CD. The natural history of tardive dystonia. A long-term follow-up study of 107 cases. Brain 1998;121:2053-2066.
32. Stacy M, Jankovic J. Tardive tremor. Mov Disord 1992;7:53-57.
33. Christensen E, Møller JE, Faurbye A. Neuropathological investigation of 28 brains from patients with dyskinesia. Acta Psychiat Scand 1970;46:14-23.
34. Egan M, Apud J, Wyatt RJ. Treatment of tardive dyskinesia. Schizophr Bull 1997;23:583-609.
35. Delfs JM, Ellison GD, Mercugliano M, Chesselet MF. Expression of glutamic acid decarboxylase mRNA in striatum and pallidum in an animal model of tardive dyskinesia. Exp Neurol 1995;133:175-188.
36. Sakai K, Gao XM, Hashimoto T, Tamminga CA. Traditional and new antipsychotic drugs differentially alter neurotransmission markers in basal ganglia-thalamocortical neural pathways. Synapse 2001;39:152-160.
37. Sagara Y. Induction of reactive oxygen species in neurons by haloperidol. J Neurochem 1998;71:1002-1012.
38. Naidu PS, Singh A, Kulkarni SK. Carvedilol attenuates neuroleptic-induced orofacial dyskinesia: possible antioxidant mechanisms. Br J Pharmacol 2002;136:193-200.
39. Soares KVS, McGrath JJ. The treatment of tardive dyskinesia - a systematic review and meta-analysis. Schizophr Res 1999;39:1-16.
40. Adler LA, Rotrosen J, Edson R, et al. Vitamin E treatment for tardive dyskinesia. Arch Gen Psychiatry 1999;56:836-841.
41. Shamir E, Barak Y, Shalman I, et al. Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Arch Gen Psychiatry 2001;58:1049-1052.
42. Tsai G, Goff DC, Chang RW, et al. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am J Psychiatry 1998;155:1207-1213.
43. König P, Chwatal K, Havelec L, et al. Amantadine versus biperiden: a double-blind study of treatment efficacy in neuroleptic extrapyramidal movement disorders. Neuropsychobiology 1996;33:80-84.
44. Angus S, Sugars J, Boltezar R, et al. A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia. J Clin Psychopharmacol 1997;17:88-91.
45. Roberts MS, McLean S, Millingen KS, Galloway HM. The pharmacokinetics of tetrabenazine and its hydroxy metabolite in patients treated for involuntary movement disorders. Eur J Clin Pharmacol 1986;29:703-708.
46. Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997;48:358-362.
47. Tarsy D, Kaufman D, Sethi KD, et al. An open-label study of botulinum toxin A for treatment of tardive dystonia. Clin Neuropharmacol 1997;20:90-93.
48. Lemer V, Miodownik C, Kaptsan A, et al. Vitamin B6 in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry 2001;158:1511-1514.
49. Weetman J, Anderson IM, Gregory RP, Gil SS. Bilateral posteroventral pallidotomy for severe antipsychotic induced tardive dyskinesia and dystonia. J Neurol Neurosurg Psychiat 1997;63:554-556.
50. Wang Y, Turnbull I, Calne S, et al. Pallidotomy for tardive dyskinesia. Lancet 1997;349:777-778.
51. Trottenberg T, Paul G, Meissner W, et al. Pallidal and thalamic neurostimulation in severe dystonia. J Neurol Neurosurg Psychiatry 2001;70:557-559.
52. Sutcher H, Soderstrom J, Perry RD. Tardive dyskinesia: dental prosthetic therapy. Panminerva Med 1998;40:154-156.